<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5072">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01176773</url>
  </required_header>
  <id_info>
    <org_study_id>S15-002</org_study_id>
    <nct_id>NCT01176773</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Juvéderm® Ultra Lip Injectable Gel for Lip Enhancement</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allergan Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allergan</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the safety and effectiveness of Juvéderm® Ultra
      Lip Injectable Gel for lip enhancement.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Investigator Assessment of the Subject's Overall Lip Fullness on the 4-point Lip Fullness Scale</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The responder rate at 3 months, where a responder was defined as an improvement (increase) on the Lip Fullness Scale of ≥ 1 grade compared with the baseline assessment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Perioral Line Severity Using the Perioral Line Severity Scale</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score on 4-point Perioral Line Severity Scale, where 0 is none and 3 is severe. A decreased score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Oral Commissures Using the Oral Commissures Severity Scale</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Score on 4-point Oral Commissures Severity Scale, where 0 is none and 3 is severe. A decreased score indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Appearance and Feel of the Lips Using the Look and Feel Scale</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>The scale consists of subcategories pertaining to how the subjects perceived aspects of their lips (e.g., softness, smoothness, etc). The outcome measure is the percentage of subjects who scored 0-3 on an 11-point scale, where a lower score on the scale indicates a positive result.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Who Attain Their Lip Treatment Goal</measure>
    <time_frame>1-12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Prior to treatment and in consultation with the Investigator, the subject establishes a realistic lip fullness treatment goal. At follow-up, attainment is assessed as yes or no. The outcome measure is the percentage of subjects responding &quot;yes&quot; as to whether their pre-established lip fullness treatment goal had been attained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Lip Enhancement</condition>
  <arm_group>
    <arm_group_label>Juvéderm® Ultra Lip Injectable Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hyaluronic acid gel</intervention_name>
    <description>Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL</description>
    <arm_group_label>Juvéderm® Ultra Lip Injectable Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  Desire enhancement of his/her vermilion borders and/or vermilion mucosa Cupid's bow,
             philtral columns, perioral lines, and oral commissures may also be treated

          -  Have a baseline score of Minimal of Mild, as assessed by the Investigator according
             to the 4-point Lip Fullness Scale (Minimal, Mild, Moderate, Marked)

          -  Have established a realistic Lip Fullness treatment goal that Investigator agrees is
             achievable

        Exclusion Criteria:

          -  Have undergone cosmetic facial, lip or perioral procedures [e.g., face-lift or other
             surgeries which may alter the appearance of the lips or perioral area (laser,
             photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or
             greater depth chemical peel, or other ablative procedures), tissue augmentation with
             dermal fillers or fat injections, or mesotherapy] anywhere in the face or neck, or
             BOTOX® Cosmetic injections in the lower face (below the orbital rim), within 6 months
             prior to entry in the study or be planning to undergo any of these procedures at any
             time during the study. Note: Prior treatment with Hyaluronic Acid fillers and/or
             collage is allowed, provided the treatment was administered not less than 6 months
             prior to study entry

          -  Have ever received semi-permanent fillers or permanent facial implants (e.g., calcium
             hydroxylapatite, L-polylactic acid, PMMA, silicone, ePTFE) anywhere in the lips, or
             be planning to be implanted with any of these products at any time during the study

          -  Have a history of anaphylaxis, multiple severe allergies, atopy, allergy to local
             anaesthesia agents, hyaluronic acid products or Streptococcal protein, or be planning
             to undergo desensitization therapy during the term of the study

          -  Are pregnant, lactating, or planning to become pregnant at any time during the study

          -  Have received investigational product within 30 days prior to study enrollment or be
             planning to participate in another investigation during the course of this study

          -  Have a condition or be in a situation that, in the Investigator's opinion, may put
             the subject at significant risk, may confound the study results, or may interfere
             significantly with the subject's participation in the study

          -  Have a history of or currently suffer from autoimmune disease

          -  Have a history of treatment with interferon for chronic hepatitis C

          -  Be on an ongoing regimen of anti-coagulation therapy (e.g., warfarin) or have taken
             NSAIDs (e.g. aspirin, ibuprofen) or other substances known to increase coagulation
             time (e.g. herbal supplements with garlic or Gingko Biloba) within 10 days of
             undergoing study device injection. Note: Study device injection may be delayed as
             necessary to accommodate this 10-day wash out period
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cheadle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Halesowen</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Sutton Coldfield</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Italy</country>
  </removed_countries>
  <reference>
    <citation>Eccleston D, Murphy DK. Juvéderm(®) Volbella™ in the perioral area: a 12-month prospective, multicenter, open-label study. Clin Cosmet Investig Dermatol. 2012;5:167-72. doi: 10.2147/CCID.S35800. Epub 2012 Oct 26.</citation>
    <PMID>23152693</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>October 6, 2014</lastchanged_date>
  <firstreceived_date>March 23, 2010</firstreceived_date>
  <firstreceived_results_date>June 7, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Juvéderm® Ultra Lip Injectable Gel</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Screen Failure</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Juvéderm® Ultra Lip Injectable Gel</title>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="54"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="50.2" spread="12.14"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United Kingdom</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="60"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Investigator Assessment of the Subject's Overall Lip Fullness on the 4-point Lip Fullness Scale</title>
        <description>The responder rate at 3 months, where a responder was defined as an improvement (increase) on the Lip Fullness Scale of ≥ 1 grade compared with the baseline assessment</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm® Ultra Lip Injectable Gel</title>
            <description>The Investigator determined the appropriate volume to inject based on clinical experience and the subject's cosmetic goals for lip enhancement.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="59"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Assessment of the Subject's Overall Lip Fullness on the 4-point Lip Fullness Scale</title>
            <description>The responder rate at 3 months, where a responder was defined as an improvement (increase) on the Lip Fullness Scale of ≥ 1 grade compared with the baseline assessment</description>
            <units>percentage of responders</units>
            <param>Number</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="93.2" lower_limit="83.54" upper_limit="98.12"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Perioral Line Severity Using the Perioral Line Severity Scale</title>
        <description>Score on 4-point Perioral Line Severity Scale, where 0 is none and 3 is severe. A decreased score indicates improvement.</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who were treated for perioral lines</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm® Ultra Lip Injectable Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="26"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Assessment of Perioral Line Severity Using the Perioral Line Severity Scale</title>
            <description>Score on 4-point Perioral Line Severity Scale, where 0 is none and 3 is severe. A decreased score indicates improvement.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" spread="0.69"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Oral Commissures Using the Oral Commissures Severity Scale</title>
        <description>Score on 4-point Oral Commissures Severity Scale, where 0 is none and 3 is severe. A decreased score indicates improvement.</description>
        <time_frame>12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who were treated in their oral commissures</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm® Ultra Lip Injectable Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Investigator Assessment of Oral Commissures Using the Oral Commissures Severity Scale</title>
            <description>Score on 4-point Oral Commissures Severity Scale, where 0 is none and 3 is severe. A decreased score indicates improvement.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.6" spread="0.85"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Appearance and Feel of the Lips Using the Look and Feel Scale</title>
        <description>The scale consists of subcategories pertaining to how the subjects perceived aspects of their lips (e.g., softness, smoothness, etc). The outcome measure is the percentage of subjects who scored 0-3 on an 11-point scale, where a lower score on the scale indicates a positive result.</description>
        <time_frame>3 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects with a Look and Feel assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm® Ultra Lip Injectable Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Subject Assessment of Appearance and Feel of the Lips Using the Look and Feel Scale</title>
            <description>The scale consists of subcategories pertaining to how the subjects perceived aspects of their lips (e.g., softness, smoothness, etc). The outcome measure is the percentage of subjects who scored 0-3 on an 11-point scale, where a lower score on the scale indicates a positive result.</description>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Lips and Mouth Feel Soft</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="72.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lips Feel Smooth</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="81.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lips Feel Natural</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="93.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lips Look Even</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="88.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lips Look Natural</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89.8"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Who Attain Their Lip Treatment Goal</title>
        <description>Prior to treatment and in consultation with the Investigator, the subject establishes a realistic lip fullness treatment goal. At follow-up, attainment is assessed as yes or no. The outcome measure is the percentage of subjects responding &quot;yes&quot; as to whether their pre-established lip fullness treatment goal had been attained.</description>
        <time_frame>1-12 months</time_frame>
        <safety_issue>No</safety_issue>
        <population>All subjects who provided a lip fullness goal achievement assessment</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm® Ultra Lip Injectable Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Who Attain Their Lip Treatment Goal</title>
            <description>Prior to treatment and in consultation with the Investigator, the subject establishes a realistic lip fullness treatment goal. At follow-up, attainment is assessed as yes or no. The outcome measure is the percentage of subjects responding &quot;yes&quot; as to whether their pre-established lip fullness treatment goal had been attained.</description>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Month 1 (n = 58)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 3 (n = 59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6 (n = 59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 9 (n = 59)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="86.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 12 (n = 58)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="56.9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Events</title>
        <time_frame>12 months</time_frame>
        <safety_issue>Yes</safety_issue>
        <population>Intent-to-treat</population>
        <group_list>
          <group group_id="O1">
            <title>Juvéderm® Ultra Lip Injectable Gel</title>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="60"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Adverse Events</title>
            <units>percentage of subjects</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Bruising</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="51.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Swelling</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Lumps/bumps</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="8.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Juvéderm® Ultra Lip Injectable Gel</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 4.5.2</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nerve compression (unrelated to device)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
              <event>
                <sub_title>Lumps/bumps</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="60"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 120 days from the time submitted to the sponsor for review. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Allergan Medical</organization>
      <phone>(805) 961-5000</phone>
      <email>devicetrials@allergan.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
